What is Ciliatech?
Ciliatech is a medical technology company specializing in the field of ophthalmology. The company is dedicated to developing a groundbreaking class of intraocular implants designed to offer a durable and minimally invasive solution for glaucoma treatment. Addressing the growing global need for effective glaucoma management, Ciliatech's innovative implant aims to set a new standard by providing a safer, more efficient, and longer-lasting alternative to existing therapeutic options for patients suffering from this progressive eye condition.
How much funding has Ciliatech raised?
Ciliatech has raised a total of $3.9M across 1 funding round:
Series A
$3.9M
Series A (2023): $3.9M, investors not publicly disclosed
What's next for Ciliatech?
The substantial enterprise-level financing and recent strategic investment signal a critical growth phase for Ciliatech. This capital infusion is expected to accelerate the company's product development pipeline, facilitate clinical trials, and prepare for potential market entry. The focus on glaucoma, a condition with significant unmet needs, positions Ciliatech for substantial impact. Future strategic partnerships and further funding rounds will likely be contingent on successful clinical outcomes and regulatory approvals, paving the way for Ciliatech to establish its innovative implant as a leading treatment modality.
See full Ciliatech company page
